Stockreport

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Scholar Rock Holding Corporation  (SRRK) 
Last scholar rock holding corporation earnings: 11/12 07:30 am Check Earnings Report
PDF Topline results expected in 2Q 2025 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innova [Read more]